Market news

Looking back on branded pharmaceuticals stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Merck (NYSE:MRK) and its peers.

Merck spent most of a decade trailing the S&P 500, then something unusual happened in a single year that changed the entire math. Whether that burst signals a new chapter or a one-time event comes down to a drug patent clock and a $14.8 billion bet on acquisitions.

Deals involving novel cancer therapies and weight-loss drugs reinforce the growing global appeal of Chinese biotech innovation.

On September 24, Merck & Co., Inc. (NYSE:MRK) announced positive topline results from its pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig, a potentially first-in-class tri-specific Wnt pathway agonist, in adults with diabetic macular edema (DME). At 52 weeks, both the 0.5 mg and 0.8 mg doses met the primary endpoint by demonstrating non-inferiority to the […]

Merck and Daiichi Sankyo voluntarily withdrew their FDA application for a lung cancer drug due to insufficient data, though trials continue.

MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.

FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.

Key Stats for Merck Stock52-Week Range: $78 to $157Market Cap: around $367 billionStreet Mean Target: around $154Forward 2-Year Revenue Growth (CAGR): around 4%NTM EV/EBITDA: around 17xLTM Gross Margin: 75. 9%Dividend Yield: 2.

Bio-Techne Corporation (NASDAQ:TECH) shareholders voted on September 23 to approve the company’s acquisition by Merck KGaA of Darmstadt, Germany. The German group is paying $73 a share in cash, valuing the business at about $11.3 billion including debt. They also voted down the executive compensation proposal attached to the deal, which is an unusual pairing. […]

Merck & Co (NYSE:MRK) has outperformed the market over the past 5 years by 3.0% on an annualized basis producing an average annual return of 15.2%. Currently, Merck & Co has a market capitalization of $364.51

MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.

Moderna shares rose 0.09% after hours Thursday as investors eyed upcoming oncology data at a major European conference.

Wall Street loves a good upgrade, especially when the stock has already doubled and the analyst can explain why everyone should have owned it six months ago. One place I look for ideas is the investment portfolios of

Merck reports Phase 2b/3 BRUNELLO trial data for remigromig in DME, achieving vision non-inferiority to ranibizumab alongside elevated adverse event rates.

Merck (MRK) succeeds in a Phase 2b/3 trial for diabetic macular edema as intravitreal injection remigromig shows non-inferiority to Roche's Lucentis. Read more here.

In the latest trading session, Merck (MRK) closed at $148.08, marking a -1.88% move from the previous day.

Merck & Co Inc (NYSE:MRK, XETRA:6MK) could see its shares re-rated as a series of clinical catalysts across its oncology and broader pipeline approach over the next 12 to 18 months, Bank of America (BofA) said while maintaining its 'buy' rating. The bank hosted investor meetings with...

Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.

Merck (NYSE:MRK) received Japanese approval for KEYTRUDA QLEX (KEYJECT), its first subcutaneous KEYTRUDA formulation, for all existing local indications. The new subcutaneous version offers an alternative to intravenous dosing, aimed at faster administration for patients and clinicians. This approval broadens Merck's oncology treatment options in Japan, a key international market for its immunotherapy portfolio. The KEYTRUDA QLEX subcutaneous green light in Japan matters. However, investors...

Merck (MRK) and Bristol Myers Squibb (BMY) win FDA nod for a label update for Winrevair, their jointly marketed drug for pulmonary arterial hypertension. Read more here.

Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

MRK's Keytruda plus Padcev combo gets CHMP backing as perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer.

Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

Merck (MRK) outlook turns bearish after a 92% run: valuation now rich and overbought on mRNA vaccine hype.

RAHWAY, N.J., September 21, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use for all indications approved in Japan for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. In Japan, KEYJECT®, for subcutaneous injection is the planned trademark for KEYTRUDA QLEX. KEYJECT can be administer

Both Amgen and Merck write quarterly checks and raise them every year, but only one has the portfolio depth to keep growing that payout through the next brutal round of patent expirations. The answer may surprise investors who have been watching Merck's blockbuster momentum.

Merck (NYSE:MRK) received a positive opinion from the EMA’s CHMP for KEYTRUDA plus Padcev in muscle-invasive bladder cancer. The CHMP backed the combination as perioperative therapy for adults with resectable muscle-invasive bladder cancer in the European Union. If endorsed by the European Commission, the regimen would be the first PD-1 inhibitor plus antibody-drug conjugate option for this setting in Europe. The CHMP verdict on KEYTRUDA plus Padcev is only one piece of the wider Merck story...

Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.

RAHWAY, N.J., September 18, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adults with resectable muscle-invas